A new treatment approach for those with Diabetes 2 with a drug that targets activity in the brain, Cycloset. The drug has been used to treat Parkinson’s disease and it appears via the clinical trials that it is helping control the rise in blood sugar and also can reduce the rate of heart attacks. Side effects are nausea and dizziness.
This is not approved for Diabetes 1 patients. BD
WEDNESDAY, May 6 (HealthDay News) -- Cycloset (bromocriptine), a drug that takes the novel approach of managing blood sugar via the
brain, has been approved by the U.S. Food and Drug Administration, maker VeroScience Inc. said Wednesday.
The drug, previously prescribed in higher amounts to treat Parkinson's disease, targets a brain chemical that ultimately is involved in regulating metabolism, reports the Associated Press.
A single dose taken in the morning helped control the rise in blood sugar that typically follows daily meals. After six months of use, 35 percent of people who took Cycloset had recommended blood sugar levels, compared with 10 percent of diabetics who took a non-medicinal placebo, the drug's maker said.
Huh! Curious to hear how well it was tolerated.
ReplyDelete